13F HOLDINGS REPORT
Omega Fund Management, LLC
Quarter ended Q4 2024 · Filed February 14, 2025 · Accession 0000950123-25-002355
Total Value
$120.7M
Positions
11
Other Managers
0
Confidential Omitted
No
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Bicara Therapeutics Inc. | BCAX | 2,204,650 | $38.4M | 31.82% |
| 2 | Nuvation Bio | NUVB | 13,072,340 | $34.8M | 28.81% |
| 3 | Replimune Group | REPL | 1,975,203 | $23.9M | 19.82% |
| 4 | Lexeo Therapeutics | LXEO | 1,184,636 | $7.8M | 6.46% |
| 5 | Alumis Inc | ALMS | 653,223 | $5.1M | 4.25% |
| 6 | Ikena Oncology | 45175G108 | 2,249,123 | $3.7M | 3.06% |
| 7 | enGene Holdings Inc. | ENGNW | 526,357 | $3.5M | 2.90% |
| 8 | Immunic Inc | IMUX | 1,788,160 | $1.8M | 1.48% |
| 9 | Sana Biotechnology, Inc. | SANA | 843,750 | $1.4M | 1.14% |
| 10 | enGene Holdings Inc. | ENGNW | 321,502 | $271,123 | 0.22% |
| 11 | Syros Pharmaceuticals | 87184Q206 | 251,270 | $57,792 | 0.05% |